应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
REGN 再生元制药公司
交易中 01-12 09:45:29 EST
798.46
+1.91
+0.24%
最高
811.09
最低
786.15
成交量
7.93万
今开
810.00
昨收
796.55
日振幅
3.13%
总市值
839.17亿
流通市值
824.83亿
总股本
1.05亿
成交额
6,341万
换手率
0.08%
流通股本
1.03亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
再生元制药公司：IPR&D费用将导致2025年第四季度调整后每股收益减少0.14美元——SEC文件披露
美股速递 · 19:51
再生元制药公司：IPR&D费用将导致2025年第四季度调整后每股收益减少0.14美元——SEC文件披露
再生元制药公司跌0.13% 股价跌破800美元大关
市场透视 · 01-10 00:36
再生元制药公司跌0.13% 股价跌破800美元大关
再生元制药公司获美银全球研究上调评级至“买入” 盘前股价应声上涨2.3%
美股速递 · 01-07
再生元制药公司获美银全球研究上调评级至“买入” 盘前股价应声上涨2.3%
美银全球研究上调再生元制药评级至买入 目标价跃升至860美元
美股速递 · 01-07
美银全球研究上调再生元制药评级至买入 目标价跃升至860美元
新闻发布：赛诺菲与再生元制药公司的Dupixent在日本获得批准，用于6至11岁支气管哮喘儿童的治疗
美股速递 · 2025-12-23
新闻发布：赛诺菲与再生元制药公司的Dupixent在日本获得批准，用于6至11岁支气管哮喘儿童的治疗
默沙东(MRK.US)、施贵宝(BMY.US)等多家药企同意下调美国药价 以换取特朗普政府关税豁免和政策支持
智通财经 · 2025-12-20
默沙东(MRK.US)、施贵宝(BMY.US)等多家药企同意下调美国药价 以换取特朗普政府关税豁免和政策支持
欧洲药品管理局推荐扩展Arexvy、Aspaveli、Dovprela、Elucirem、Eylea、Nucala、Recarbrio、Simponi、Uplizna、Vueway的适应症
美股速递 · 2025-12-12
欧洲药品管理局推荐扩展Arexvy、Aspaveli、Dovprela、Elucirem、Eylea、Nucala、Recarbrio、Simponi、Uplizna、Vueway的适应症
独家：美国FDA促请审评员加快对礼来减肥药的评估 - 内部文件
美股速递 · 2025-12-12
独家：美国FDA促请审评员加快对礼来减肥药的评估 - 内部文件
Lynozyfic™（Linvoseltamab）单药治疗新诊断多发性骨髓瘤（Ndmm）显著反应，支持作为一线治疗潜在基础的合理性
美股速递 · 2025-12-08
Lynozyfic™（Linvoseltamab）单药治疗新诊断多发性骨髓瘤（Ndmm）显著反应，支持作为一线治疗潜在基础的合理性
再生元制药公司：公司将50:50共享全球开发费用和未来利润
美股速递 · 2025-12-01
再生元制药公司：公司将50:50共享全球开发费用和未来利润
再生元制药公司与Tessera Therapeutics联合开发针对α-1抗胰蛋白酶缺乏症的研究性基因编辑治疗Tsra-196
美股速递 · 2025-12-01
再生元制药公司与Tessera Therapeutics联合开发针对α-1抗胰蛋白酶缺乏症的研究性基因编辑治疗Tsra-196
汇丰：首予再生元制药(REGN.US)“买入”评级 看好Eylea HD放量及肿瘤管线多点催化
智通财经 · 2025-11-25
汇丰：首予再生元制药(REGN.US)“买入”评级 看好Eylea HD放量及肿瘤管线多点催化
新闻稿：Dupixent，由赛诺菲和再生元制药公司开发，成为十多年来欧盟首个针对特发性慢性荨麻疹的靶向药物
美股速递 · 2025-11-25
新闻稿：Dupixent，由赛诺菲和再生元制药公司开发，成为十多年来欧盟首个针对特发性慢性荨麻疹的靶向药物
Dupixent®（Dupilumab）成为十多年来欧洲联盟（EU）首个获批的针对慢性自发性荨麻疹（CSU）的靶向药物
美股速递 · 2025-11-25
Dupixent®（Dupilumab）成为十多年来欧洲联盟（EU）首个获批的针对慢性自发性荨麻疹（CSU）的靶向药物
一周美股牛榜 | 再生元上周飙升9%；谷歌和罗斯百货扬8%；美敦力升6%
老虎资讯综合 · 2025-11-24
一周美股牛榜 | 再生元上周飙升9%；谷歌和罗斯百货扬8%；美敦力升6%
再生元制药公司 - 与Catalent Indiana协调解决2025年7月FDA一般现场检查中发现的问题
美股速递 · 2025-11-20
再生元制药公司 - 与Catalent Indiana协调解决2025年7月FDA一般现场检查中发现的问题
Eylea Hd® (Aflibercept) 注射剂 8 毫克通过 FDA 批准用于治疗视网膜静脉阻塞后的黄斑水肿，并可在批准适应症中进行每月给药
美股速递 · 2025-11-20
Eylea Hd® (Aflibercept) 注射剂 8 毫克通过 FDA 批准用于治疗视网膜静脉阻塞后的黄斑水肿，并可在批准适应症中进行每月给药
再生元制药公司杜比尤单抗关键试验达成所有主要和次要终点，显著减轻过敏性真菌性鼻窦炎症状；sBLA获得FDA优先审查
投资观察 · 2025-11-20
再生元制药公司杜比尤单抗关键试验达成所有主要和次要终点，显著减轻过敏性真菌性鼻窦炎症状；sBLA获得FDA优先审查
再生元制药公司Libtayo®（Cemiplimab）在欧盟获得批准，成为首个也是唯一用于高复发风险的皮肤鳞状细胞癌术后及放疗辅助治疗的免疫疗法
美股速递 · 2025-11-19
再生元制药公司Libtayo®（Cemiplimab）在欧盟获得批准，成为首个也是唯一用于高复发风险的皮肤鳞状细胞癌术后及放疗辅助治疗的免疫疗法
赛诺菲与再生元的Dupixent达成关键终点，获FDA优先审查接受
投资观察 · 2025-11-07
赛诺菲与再生元的Dupixent达成关键终点，获FDA优先审查接受
加载更多
公司概况
公司名称：
再生元制药公司
所属市场：
NASDAQ
上市日期：
--
主营业务：
再生元制药公司于1988年在纽约州成立。再生元制药公司是一家完全集成的生物技术公司，它发现、发明、开发、制造和商业化治疗严重疾病的药物。其正在开发的商业化药物和候选产品旨在帮助患有眼疾、过敏性和炎症性疾病、癌症、心血管和代谢性疾病、疼痛、传染病和罕见疾病的患者。它的核心业务战略是在基础科学研究和发现启用技术方面保持坚实的基础，并建立在临床开发、制造和商业能力的基础上。其目标是继续成为一家综合性、多产品的生物技术公司，为患者和医疗专业人员提供预防和治疗人类疾病的重要选择。
发行价格：
--
{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"再生元制药公司","latestPrice":798.455,"timestamp":1768229127261,"preClose":796.55,"halted":0,"volume":79305,"delay":0,"floatShares":103302739,"shares":105099464,"eps":41.59414,"marketStatus":"交易中","change":1.905,"latestTime":"01-12 09:45:29 EST","open":810,"high":811.09,"low":786.153,"amount":63414102.015,"amplitude":0.031306,"askPrice":798.4,"askSize":3,"bidPrice":796.3,"bidSize":2,"shortable":3,"etf":0,"ttmEps":41.59414,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1768251600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":796.55,"dividendRate":0.004409,"preHourTrading":{"tag":"盘前","latestPrice":810,"preClose":796.55,"latestTime":"09:29 EST","volume":3423,"amount":2759334.0411,"timestamp":1768228199936},"postHourTrading":{"tag":"盘后","latestPrice":796.55,"preClose":796.55,"latestTime":"19:45 EST","volume":16547,"amount":13180505.0532,"timestamp":1768005944642},"volumeRatio":2.014796,"impliedVol":0.3915,"impliedVolPercentile":0.4701},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"1183550675","title":"再生元制药公司：IPR&D费用将导致2025年第四季度调整后每股收益减少0.14美元——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1183550675","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183550675?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:51","pubTimestamp":1768218682,"startTime":"0","endTime":"0","summary":"根据最新提交的美国证券交易委员会（SEC）文件显示，再生元制药公司确认，一项与IPR&D（进程中的研发项目）相关的费用，预计将对2025年第四季度的调整后每股收益产生负面影响，具体减少金额为0.14美元。\n这一费用反映了公司在研发领域的持续投入与战略调整。尽管短期内会对盈利指标造成压力，但它也凸显了再生元制药长期致力于创新药物开发的决心。投资者在评估公司未来业绩时，需综合考虑此类战略性支出对长期价值创造的潜在贡献。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU2237438978.USD","LU2362541513.USD","LU1974910355.USD","LU0058720904.USD","LU2468319806.SGD","BK4139","LU2023250504.SGD","LU2362540622.SGD","LU0823416689.USD","LU0289739699.SGD","LU0114720955.EUR","LU0320765992.SGD","LU2089984988.USD","BK4585","LU1917777945.USD","LU0109394709.USD","REGN","LU2106854487.HKD","BK4588","LU0823434583.USD","LU2362541273.HKD","LU0053666078.USD","LU0823434740.USD","LU0882574055.USD"],"gpt_icon":0},{"id":"2602450584","title":"再生元制药公司跌0.13% 股价跌破800美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2602450584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602450584?lang=zh_cn&edition=full","pubTime":"2026-01-10 00:36","pubTimestamp":1767976611,"startTime":"0","endTime":"0","summary":"北京时间2026年01月10日00时36分，再生元制药公司股票出现波动，股价快速跳水0.13%。截至发稿，该股报800.00美元/股，成交量25.4784万股，换手率0.24%，振幅2.62%。最近的财报数据显示，该股实现营业收入37.54亿美元，净利润14.60亿美元，每股收益14.09美元，毛利30.96亿美元，市盈率19.18倍。再生元制药公司股票所在的生物技术行业中，整体涨幅为0.75%。再生元制药公司公司简介：再生元制药发现、开发并商业化对抗眼病、心血管疾病、癌症和炎症的产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110003651a7081e1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110003651a7081e1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0058720904.USD","LU1974910355.USD","LU0114720955.EUR","LU1917777945.USD","LU0823416689.USD","LU2362540622.SGD","LU2106854487.HKD","REGN","LU2237438978.USD","LU2023250504.SGD","LU2362541513.USD","LU2468319806.SGD","LU0823434583.USD","LU0882574055.USD","LU2362541273.HKD","BK4585","LU0289739699.SGD","LU0053666078.USD","BK4139","LU0109394709.USD","LU0889565916.HKD","BK4588","LU2089984988.USD","LU0823434740.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"1103404064","title":"再生元制药公司获美银全球研究上调评级至“买入” 盘前股价应声上涨2.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103404064","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103404064?lang=zh_cn&edition=full","pubTime":"2026-01-07 19:37","pubTimestamp":1767785828,"startTime":"0","endTime":"0","summary":"在美银全球研究将其股票评级从“跑输大盘”上调至“买入”后，再生元制药公司（Regeneron Pharmaceuticals）股价在盘前交易时段应声走高，涨幅达2.3%。\n此次评级上调反映了市场对该公司前景的积极预期转变，并直接提振了投资者信心，推动其股价在开盘前显著上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434583.USD","REGN","LU0114720955.EUR","LU2106854487.HKD","LU0889565916.HKD","LU0823434740.USD","LU0882574055.USD","LU2362541273.HKD","LU2089984988.USD","LU1974910355.USD","BK4588","LU2362541513.USD","LU0320765992.SGD","LU1917777945.USD","LU0289739699.SGD","BK4585","LU0053666078.USD","BK4139","LU0109394709.USD","LU2237438978.USD","LU0823416689.USD","LU2362540622.SGD","LU2468319806.SGD","LU0058720904.USD","LU2023250504.SGD"],"gpt_icon":0},{"id":"1187319297","title":"美银全球研究上调再生元制药评级至买入 目标价跃升至860美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187319297","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187319297?lang=zh_cn&edition=full","pubTime":"2026-01-07 19:27","pubTimestamp":1767785239,"startTime":"0","endTime":"0","summary":"美银全球研究（Bofa Global Research）发布最新报告，将再生元制药公司的投资评级从\"表现不佳\"大幅上调至\"买入\"级别。与此同时，该机构将其目标股价从每股627美元显著提升至860美元，显示出对该公司未来业绩的强劲信心。\n此次评级调整反映了分析师对再生元制药核心业务增长潜力的重新评估。目标价的大幅上调表明，美银全球研究认为该公司在医药研发领域的领先地位，以及其创新药物管线的商业价值尚未被市场充分定价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434583.USD","REGN","LU0114720955.EUR","LU2106854487.HKD","LU0889565916.HKD","LU0823434740.USD","LU0882574055.USD","LU2362541273.HKD","LU2089984988.USD","LU1974910355.USD","BK4588","LU2362541513.USD","LU0320765992.SGD","LU1917777945.USD","LU0289739699.SGD","BK4585","LU0053666078.USD","BK4139","LU0109394709.USD","LU2237438978.USD","LU0823416689.USD","LU2362540622.SGD","LU2468319806.SGD","LU0058720904.USD","LU2023250504.SGD"],"gpt_icon":0},{"id":"1165078073","title":"新闻发布：赛诺菲与再生元制药公司的Dupixent在日本获得批准，用于6至11岁支气管哮喘儿童的治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1165078073","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165078073?lang=zh_cn&edition=full","pubTime":"2025-12-23 14:06","pubTimestamp":1766469989,"startTime":"0","endTime":"0","summary":"新闻发布：赛诺菲与再生元制药公司的Dupixent在日本获得批准，用于6至11岁支气管哮喘儿童的治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1974910355.USD","LU0823434740.USD","LU1917777945.USD","LU2106854487.HKD","BK4139","LU0823434583.USD","LU0889565916.HKD","LU0320765992.SGD","LU0823416689.USD","LU2237438978.USD","LU2362541273.HKD","LU0882574055.USD","BK4585","BK4588","LU0114720955.EUR","LU0109394709.USD","LU2089984988.USD","LU0058720904.USD","LU2362540622.SGD","LU0289739699.SGD","LU2468319806.SGD","LU2023250504.SGD","LU0053666078.USD","LU2362541513.USD","REGN"],"gpt_icon":0},{"id":"2592139231","title":"默沙东(MRK.US)、施贵宝(BMY.US)等多家药企同意下调美国药价 以换取特朗普政府关税豁免和政策支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2592139231","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592139231?lang=zh_cn&edition=full","pubTime":"2025-12-20 07:00","pubTimestamp":1766185200,"startTime":"0","endTime":"0","summary":"美国总统特朗普推动将美国药价与海外低价市场挂钩之际，多家美国及欧洲大型制药企业近日与白宫达成协议，同意自愿下调在美销售的药品价格，以换取关税豁免和政策支持。在此次协议中，最受市场关注的是施贵宝的让利承诺。特朗普在周五的公开活动上表示，今年7月他致信要求降价的17家大型制药企业中，已有14家同意大幅下调药价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"2acbaf8fbf691a451fa9ea170ee88816","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2106854487.HKD","LU1116320737.USD","SG9999015341.SGD","BK4007","BK4588","IE00BLSP4239.USD","LU1093756325.SGD","LU0648001328.SGD","LU0211331839.USD","GILD","LU1941712264.USD","LU1057294990.SGD","IE00BBT3K403.USD","SG9999014575.USD","LU1201861249.SGD","IE0009355771.USD","LU1571399168.USD","LU2023250504.SGD","LU2089984988.USD","LU1035773651.USD","LU1061106388.HKD","LU2468319806.SGD","LU0267386448.USD","LU1023059063.AUD","LU0985320562.USD","IE00B1BXHZ80.USD","LU0098860793.USD","LU2361044865.SGD","LU0289739699.SGD","LU0861579265.USD","LU1989772923.USD","LU2361044949.HKD","LU0096364046.USD","LU1430594728.SGD","BK4532","BMY","AMGN","LU2360032135.SGD","IE00BJT1NW94.SGD","JNJ","LU1093756168.USD","LU0265550359.USD","LU0985481810.HKD","LU1868836914.USD","LU1868836757.USD","SG9999001176.USD","LU0130517989.USD","IE000M9KFDE8.USD","LU0114720955.EUR","IE00BN8TJ469.HKD","LU2324357040.USD","LU2461242641.AUD","LU0265550946.USD","NVS","ABBV","LU1670711040.USD","LU0203347892.USD","LU2125154935.USD","IE00BLSP4452.SGD","LU0456855351.SGD","REGN","LU0203345920.USD","LU2125154778.USD","SG9999002232.USD","LU1868837300.USD","IE00B2B36J28.USD","SG9999014559.SGD","LU1066053197.SGD","BK4533","LU1032466523.USD","SNY","LU1699723380.USD","LU2361045086.USD","LU0965508806.USD","LU0321505439.SGD","LU1670711123.USD","SG9999002224.SGD","BK4550","LU0130102774.USD","LU2133065610.SGD","IE00BFTCPJ56.SGD","LU1323610961.USD","LU1983299246.USD","BK4581","LU0882574055.USD","LU1069347547.HKD","GSK","LU0965509010.AUD","LU0225771236.USD","LU1291159041.SGD","SG9999001176.SGD","SG9999013999.USD","LU0070302665.USD","LU0238689110.USD","SGXZ57979304.SGD","LU1261432733.SGD","LU1934455863.HKD","IE00BJJMRZ35.SGD","LU0237698245.USD","LU0058720904.USD","BK4585","LU0122379950.USD","LU0306806265.USD","LU1929549753.HKD","LU0965509101.SGD","LU0208291251.USD","LU0106261372.USD","SG9999014542.SGD","LU1941712348.USD","LU2242646821.SGD","LU1670710588.SGD","LU1868836591.USD","LU1974910355.USD","BK4559","LU2023250843.SGD","LU1162221912.USD","LU2112291526.USD","LU0225284248.USD","IE00BFXG1179.USD","SG9999001440.SGD","IE0002141913.USD","LU0234572021.USD","LU0306807586.USD","LU1066051498.USD","LU1934455277.USD","LU1116320901.HKD","LU1917777945.USD","LU1989772840.SGD","LU1868837136.USD","LU0965509283.SGD","BK4516","LU2242652126.USD","AZN","LU0061475181.USD","LU1037948897.HKD","LU1074936037.SGD","LU1037948541.HKD","LU1585245621.USD","SG9999015358.SGD","BK4534","LU0320765646.SGD","SG9999014567.USD","LU0006306889.USD","LU0477156953.USD","LU1989771016.USD","LU1670710661.SGD","LU0320765489.SGD","LU1718418525.SGD","MRK","LU1934455194.USD","04332","LU0980610538.SGD","LU1066051811.HKD","ROG","IE00B4R5TH58.HKD","LU0266013472.USD","LU1066051225.USD","LU0868494617.USD","LU0321505868.SGD","IE00BSNM7G36.USD"],"gpt_icon":1},{"id":"1164632612","title":"欧洲药品管理局推荐扩展Arexvy、Aspaveli、Dovprela、Elucirem、Eylea、Nucala、Recarbrio、Simponi、Uplizna、Vueway的适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1164632612","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164632612?lang=zh_cn&edition=full","pubTime":"2025-12-12 21:50","pubTimestamp":1765547422,"startTime":"0","endTime":"0","summary":"欧洲药品管理局（Ema）的药物评审委员会（Chmp）推荐扩展以下药物的适应症：Arexvy、Aspaveli、Dovprela、Elucirem、Eylea、Nucala、Recarbrio、Simponi、Uplizna和Vueway。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2505996681.GBP","BK4585","IE00BFTCPJ56.SGD","IE00BGHQF631.EUR","LU1023059063.AUD","IE00B19Z3B42.SGD","LU1244550221.USD","IE00BN8TJ469.HKD","IE0034235071.USD","LU1400636657.SGD","SG9999014567.USD","IE00B3PB1722.GBP","IE00BVYPNV92.GBP","LU0109394709.USD","LU2471134796.USD","BK5011","IE00BBT3K403.USD","LU1645745479.HKD","LU1035773651.USD","LU1674673428.USD","LU1732800096.USD","LU1778281490.HKD","IE00B7SZLL34.SGD","LU2362541513.USD","LU0053666078.USD","LU1935042991.SGD","LU2324357040.USD","LU2750360641.GBP","LU0466842654.USD","LU0266013472.USD","LU0124676726.USD","IE00B42XCP33.USD","LU0265550946.USD","LU2106854487.HKD","LU1934455863.HKD","LU2360032135.SGD","GSK.UK","LU0971552673.USD","SG9999001440.SGD","LU1037948541.HKD","LU0889565916.HKD","SG9999001176.USD","LU1934455194.USD","IE0002270589.USD","IE00BVYPNW00.USD","LU2461242641.AUD","LU0320765489.SGD","LU1066053197.SGD","IE00BSNM7G36.USD","SG9999015358.SGD","LU1506573853.SGD","SG9999013999.USD","LU2430703095.HKD","IE00BFXG1179.USD","LU0689626769.HKD","LU0203345920.USD","LU1280957306.USD","LU0109981661.USD","LU0058720904.USD","LU0265550359.USD","LU0345769631.USD","LU2471134523.USD","LU2471134879.HKD","LU0795875169.SGD","LU1302929846.USD","LU1069347547.HKD","SG9999014542.SGD","LU1941712264.USD","LU0345770993.USD","LU1674673691.USD","IE00BJT1NW94.SGD","IE00B3T34201.USD","IE00BWDBJ516.SGD","LU2361044949.HKD","IE0002141913.USD","LU1228905037.USD","LU0985320562.USD","LU2129689605.HKD","LU2347655156.SGD","SGXZ57979304.SGD","LU2023250504.SGD","LU0823416689.USD","LU1585245621.USD","LU0130517989.USD","LU1061106388.HKD","LU0648001328.SGD","LU0306806265.USD","LU0306807586.USD","LU1732799900.SGD","LU1066051225.USD","LU0070217475.USD","LU0238689110.USD","LU1196500208.SGD","LU1267930813.SGD","SG9999002232.USD","LU0985481810.HKD","LU0787776722.HKD","IE00BLSP4452.SGD","LU2129689431.USD","LU1116320737.USD","LU1221951129.SGD","LU1074936037.SGD","IE00BDGV0183.EUR","LU1487256676.USD","LU1670756490.USD","JNJ","LU0211331839.USD","LU1699723380.USD","LU1228905540.USD","LU2361045086.USD","LU2361044865.SGD","LU1481600234.SGD","LU1221951046.USD","LU0640476718.USD","LU1718418525.SGD","IE000M9KFDE8.USD","LU1093756325.SGD","LU1059921491.USD","LU0795875086.SGD","IE0034235303.USD","LU0823434740.USD","LU1066051498.USD","LU1496350502.SGD","LU2592432038.USD","LU0161305163.EUR","LU0432979614.USD","IE00BZ1G4Q59.USD","LU0130102774.USD","LU1894683348.USD","LU1974910355.USD","LU1046248800.SGD","LU0345769128.USD","LU1989772923.USD","SG9999014559.SGD","LU0006306889.USD","LU0575583348.USD","LU2362540622.SGD","LU2125154935.USD","LU0971552830.HKD","LU2089984988.USD","IE00B19Z3581.USD","LU1066051811.HKD","BK4588","LU1202635105.USD","LU0321505439.SGD","SG9999014575.USD","LU0477156953.USD","BK4139","LU0683600562.USD","BK4504","LU0098860793.USD","LU2023250843.SGD","SG9999015341.SGD","LU2602419157.SGD","LU1244550494.USD","SG9999001176.SGD","LU1244550577.SGD","LU2505996509.AUD","LU0965509283.SGD","LU2362541273.HKD","LU0823434583.USD","LU2125154778.USD","BK4007","LU1291159041.SGD","IE0009355771.USD","LU2750360997.AUD","LU2129689514.USD","LU1914381329.SGD","BK4592","LU0234572021.USD","LU0889566641.SGD","LU0980610538.SGD","LU1032955483.USD","LU0345770308.USD","LU1430594728.SGD","LU1098665638.USD","BK4581","LU2468319806.SGD","LU0882574055.USD","LU0203347892.USD","LU0320765992.SGD","LU0545562505.USD","LU1035777561.USD","LU1116320901.HKD","LU1201861249.SGD","LU0965508806.USD","LU0225284248.USD","LU1983299246.USD","BK4534","LU0070302665.USD","LU0106261372.USD","LU0965509101.SGD","SG9999002224.SGD","IE00BQJZX424.USD","LU0320765646.SGD","LU1261432733.SGD","BK4532","IE00B4R5TH58.HKD","LU1064927863.SGD","LU1162221912.USD","BK4559","LU1989772840.SGD","LU2471134952.CNY","IE00BJJMRZ35.SGD","BK4516","LU0289739699.SGD","BK4533","BK4550","IE00B2B36J28.USD","MRK","LU0122379950.USD","LU1032466523.USD","LU1934455277.USD","LU2133065610.SGD","LU2430703178.SGD","REGN","LU1929549753.HKD","LU1941712348.USD","LU1481599808.USD","LU1015430645.USD","BK4568","LU1917777945.USD","LU1571399168.USD","LU2237438978.USD","LU0208291251.USD","LU0965509010.AUD","LU1037948897.HKD","LU0225771236.USD","LU0114720955.EUR","LU0234570918.USD","LU1400636574.HKD","LU1093756168.USD","LU0861579265.USD","LU0912757837.SGD","LU0321505868.SGD","LU0792757196.USD","LU1309081286.SGD","LU1057294990.SGD","LU1989771016.USD","LU2112291526.USD","IE00BLSP4239.USD","IE00BKVL7J92.USD","LU1400636491.USD","LU2430703251.USD","LU1894683264.USD","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"1107092688","title":"独家：美国FDA促请审评员加快对礼来减肥药的评估 - 内部文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1107092688","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107092688?lang=zh_cn&edition=full","pubTime":"2025-12-12 19:01","pubTimestamp":1765537283,"startTime":"0","endTime":"0","summary":"独家：美国FDA促请审评员加快对礼来减肥药的评估 - 内部文件","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BK4W5M84.HKD","LU0266013472.USD","LU1917777945.USD","IE00B1XK9C88.USD","BK4534","IE00BKDWB100.SGD","LU2361045086.USD","LU0353189763.USD","LU2746668974.SGD","LU2362541513.USD","LU0079474960.USD","IE00BJJMRY28.SGD","LU0943347566.SGD","LU0432979614.USD","LU0820561909.HKD","LU1868837300.USD","LU2168564149.EUR","IE00B4R5TH58.HKD","LU2237443549.SGD","BK4533","LU1804176565.USD","LU0256863811.USD","LU0096364046.USD","LU0203202063.USD","LU1720051017.SGD","GB00BDT5M118.USD","LU1868836591.USD","SG9999018857.SGD","SG9999015978.USD","IE00BFSS7M15.SGD","LU0006306889.USD","LU0234572021.USD","LU2264538146.SGD","LU2360106947.USD","IE00B775H168.HKD","LU0471298694.HKD","SGXZ57979304.SGD","LU0466842654.USD","LU0097036916.USD","IE0005OL40V9.USD","IE00BJLML261.HKD","LU0320765992.SGD","LU0882574139.USD","LU2362541273.HKD","LU0256863902.USD","LU1551013425.SGD","LU2324357040.USD","LU1093756325.SGD","LU0471298777.SGD","LU2750360997.AUD","SG9999017495.SGD","SG9999015952.SGD","LU2108987350.USD","LU0456855351.SGD","SG9999001176.SGD","LU0106261372.USD","IE00BJJMRX11.SGD","LU0823416689.USD","LU2357305700.SGD","LU2471134879.HKD","LU1366192091.USD","LU2602419157.SGD","IE00BJJMRZ35.SGD","LU1868836757.USD","BK4007","LU1623119135.USD","IE00B4JS1V06.HKD","LU2552382058.USD","LU1548497426.USD","LU1720051108.HKD","IE00BJT1NW94.SGD","LU0323591593.USD","LU1988902786.USD","LU0203201768.USD","IE0004445015.USD","LU2106854487.HKD","LU1983299246.USD","LU1267930730.SGD","LU2063271972.USD","LU1974910355.USD","LU2462157665.USD","LU2237443622.USD","SG9999015986.USD","SGXZ31699556.SGD","LU2168563687.JPY","SG9999014906.USD","LU0823434740.USD","IE00B1BXHZ80.USD","SG9999014914.USD","LU2168564222.USD","SGXZ51526630.SGD","LU1280957306.USD","BK4581","LU1023059063.AUD","LU2471134523.USD","LU0820561818.USD","LU2417539215.USD","IE00B2B36J28.USD","LU1069344957.HKD","LU2237443465.HKD","LU0353189680.USD","LU0708995401.HKD","LU2237443895.HKD","BK4516","LU2211815571.USD","LU2746668461.USD","LU2237438978.USD","LU1232071149.USD","LU1035775433.USD","LU1712237335.SGD","LU0061475181.USD","SGXZ99366536.SGD","BK4599","LU2361044949.HKD","LU2361044865.SGD","SG9999015945.SGD","LU0053666078.USD","LU0823434583.USD","LU1868837136.USD","LU2471134952.CNY","LU2491049909.HKD","LU0889565916.HKD","IE00BFSS8Q28.SGD","BK4588","LU2168564065.EUR","LU0094547139.USD","LU0122379950.USD","LU0385154629.USD","LU0689472784.USD","LU2265009873.SGD","SG9999001176.USD","LU0238689110.USD","LU2552382215.SGD","REGN","LU0109391861.USD","LU2087625088.SGD","LU2236285917.USD","LU1064131342.USD","LU2461242641.AUD","LU0417517546.SGD","LU2237443978.SGD","LU2552382132.HKD","BK4585","LU2491050071.SGD","LU0316494557.USD","LU0058720904.USD","LU1061106388.HKD","LU1551013342.USD","LU1057294990.SGD","LU2468319806.SGD","LU0320765059.SGD","LU0683600562.USD","LU0882574055.USD","LU2491050154.USD","LU0198837287.USD","LU1868836914.USD","LU0354030438.USD","LU1989771016.USD","IE00BK4W5L77.USD","LU0109394709.USD","LLY","LU1291159041.SGD","LU2023250504.SGD","IE0009355771.USD","LU1323610961.USD","LU2168564495.EUR","SG9999013999.USD","LU0114720955.EUR","LU1127390331.HKD","BK4139","LU0354030511.USD","IE0004445239.USD","IE00BN29S564.USD","LU0640476718.USD","LU2089984988.USD","SG9999014880.SGD","SG9999018865.SGD","LU2471134796.USD","SG9999014898.SGD","SGXZ81514606.USD","LU2112291526.USD","LU1093756168.USD","IE00BWXC8680.SGD","LU2362540622.SGD","LU1814569148.SGD","IE00BFTCPJ56.SGD","LU2237443382.USD","LU0289739699.SGD","LU0786609619.USD","IE00BKPKM429.USD","IE00B7KXQ091.USD","LU2456880835.USD","LU2750360641.GBP","IE0002141913.USD","LU0787776722.HKD","LU0672654240.SGD"],"gpt_icon":0},{"id":"1123079494","title":"Lynozyfic™（Linvoseltamab）单药治疗新诊断多发性骨髓瘤（Ndmm）显著反应，支持作为一线治疗潜在基础的合理性","url":"https://stock-news.laohu8.com/highlight/detail?id=1123079494","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123079494?lang=zh_cn&edition=full","pubTime":"2025-12-08 05:32","pubTimestamp":1765143133,"startTime":"0","endTime":"0","summary":"Lynozyfic™（Linvoseltamab）单药治疗新诊断多发性骨髓瘤（Ndmm）显著反应，支持作为一线治疗潜在基础的合理性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362540622.SGD","LU0823434740.USD","LU0109394709.USD","LU1974910355.USD","LU2089984988.USD","REGN","LU2362541273.HKD","LU2106854487.HKD","LU2237438978.USD","BK4585","LU0882574055.USD","BK4139","LU0289739699.SGD","LU0053666078.USD","BK4588","LU0058720904.USD","LU2468319806.SGD","LU1917777945.USD","LU0114720955.EUR","LU0320765992.SGD","LU2362541513.USD","LU0889565916.HKD","LU0823416689.USD","LU2023250504.SGD","LU0823434583.USD"],"gpt_icon":0},{"id":"1185904287","title":"再生元制药公司：公司将50:50共享全球开发费用和未来利润","url":"https://stock-news.laohu8.com/highlight/detail?id=1185904287","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185904287?lang=zh_cn&edition=full","pubTime":"2025-12-01 20:01","pubTimestamp":1764590487,"startTime":"0","endTime":"0","summary":"再生元制药公司：公司将50:50共享全球开发费用和未来利润","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","LU0114720955.EUR","LU0289739699.SGD","LU2362541513.USD","LU2468319806.SGD","BK4588","LU0823434740.USD","LU0320765992.SGD","LU2237438978.USD","REGN","LU0109394709.USD","LU2106854487.HKD","LU2089984988.USD","BK4585","LU0823416689.USD","LU0889565916.HKD","LU2023250504.SGD","LU1974910355.USD","BK4139","LU1917777945.USD","LU0823434583.USD","LU0058720904.USD","LU2362540622.SGD","LU0882574055.USD","LU0053666078.USD"],"gpt_icon":0},{"id":"1199264050","title":"再生元制药公司与Tessera Therapeutics联合开发针对α-1抗胰蛋白酶缺乏症的研究性基因编辑治疗Tsra-196","url":"https://stock-news.laohu8.com/highlight/detail?id=1199264050","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199264050?lang=zh_cn&edition=full","pubTime":"2025-12-01 20:01","pubTimestamp":1764590470,"startTime":"0","endTime":"0","summary":"再生元制药公司与Tessera Therapeutics联合开发针对α-1抗胰蛋白酶缺乏症的研究性基因编辑治疗Tsra-196。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250504.SGD","LU1974910355.USD","LU0823434740.USD","BK4585","LU1917777945.USD","LU0289739699.SGD","LU0114720955.EUR","LU0058720904.USD","REGN","LU0823416689.USD","BK4139","LU2089984988.USD","LU2106854487.HKD","LU2468319806.SGD","LU0882574055.USD","LU2362540622.SGD","LU2362541273.HKD","LU0053666078.USD","LU0109394709.USD","LU2237438978.USD","LU0320765992.SGD","LU0823434583.USD","BK4588","LU0889565916.HKD","LU2362541513.USD"],"gpt_icon":0},{"id":"2586442054","title":"汇丰：首予再生元制药(REGN.US)“买入”评级 看好Eylea HD放量及肿瘤管线多点催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2586442054","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586442054?lang=zh_cn&edition=full","pubTime":"2025-11-25 15:32","pubTimestamp":1764055926,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，汇丰银行发表研报，首次覆盖再生元制药，并给予 “买入” 评级，目标价为890美元，核心依据包括其药物Eylea HD明年销售额的增长潜力，以及研发管线中多项癌症疗法的积极催化。分析师Yifeng Liu指出，尽管Eylea HD目前的市场渗透速度未达预期，但“与Eylea HD相关的监管风险有望在短期内得到解决，这将为2026年药物加速普及和渗透率提升奠定基础”。此外，该联合疗法用于黑色素瘤辅助治疗的III期临床数据可能于明年公布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1373216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["REGN","01477","HD","HSBC"],"gpt_icon":0},{"id":"1159316672","title":"新闻稿：Dupixent，由赛诺菲和再生元制药公司开发，成为十多年来欧盟首个针对特发性慢性荨麻疹的靶向药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1159316672","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159316672?lang=zh_cn&edition=full","pubTime":"2025-11-25 14:00","pubTimestamp":1764050418,"startTime":"0","endTime":"0","summary":"新闻稿：Dupixent，由赛诺菲和再生元制药公司开发，成为十多年来欧盟首个针对特发性慢性荨麻疹的靶向药物","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU2362540622.SGD","LU2106854487.HKD","BK4585","LU2468319806.SGD","LU0053666078.USD","LU0109394709.USD","BK4139","LU0114720955.EUR","LU2023250504.SGD","LU0289739699.SGD","LU0823434583.USD","LU0889565916.HKD","LU2089984988.USD","LU2362541513.USD","BK4588","REGN","LU0058720904.USD","LU1917777945.USD","LU0882574055.USD","LU0823434740.USD","LU1974910355.USD","LU2237438978.USD","LU0320765992.SGD","LU2362541273.HKD"],"gpt_icon":0},{"id":"1145897938","title":"Dupixent®（Dupilumab）成为十多年来欧洲联盟（EU）首个获批的针对慢性自发性荨麻疹（CSU）的靶向药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1145897938","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145897938?lang=zh_cn&edition=full","pubTime":"2025-11-25 14:00","pubTimestamp":1764050415,"startTime":"0","endTime":"0","summary":"Dupixent®（Dupilumab）成为十多年来欧洲联盟（EU）首个获批的针对慢性自发性荨麻疹（CSU）的靶向药物","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU1974910355.USD","LU0114720955.EUR","LU1917777945.USD","LU0823416689.USD","LU2362540622.SGD","LU2106854487.HKD","REGN","LU2237438978.USD","LU2023250504.SGD","LU2362541513.USD","LU2468319806.SGD","LU0823434583.USD","LU0882574055.USD","LU2362541273.HKD","BK4585","LU0289739699.SGD","LU0053666078.USD","BK4139","LU0109394709.USD","LU0889565916.HKD","BK4588","LU2089984988.USD","LU0823434740.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"1142970680","title":"一周美股牛榜 | 再生元上周飙升9%；谷歌和罗斯百货扬8%；美敦力升6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142970680","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142970680?lang=zh_cn&edition=full","pubTime":"2025-11-24 10:17","pubTimestamp":1763950659,"startTime":"0","endTime":"0","summary":"Solventum董事会已批准一项 股票回购计划，授权公司回购 最多10亿美元 的普通股。Solventum股价上周上涨 9.6%。谷歌A上周五收涨 3.5%，市值达到 3.62万亿美元，上周股价大涨 8.4%。公司第三季度销售也超出预期，上周股价上涨 8.4%。美敦力上调全年销售增长预期，因心脏设备需求强劲 $美敦力$ 第二财季业绩超出预期，并在上周二上调全年销售增长预期，因心脏设备需求旺盛，股价上周上涨 5.6%。","market":"us","thumbnail":"https://community-static.tradeup.com/news/226b03648204ea05089b5982a628b9f4","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/226b03648204ea05089b5982a628b9f4"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDT","GOOGL","ROST","REGN"],"gpt_icon":1},{"id":"1140117891","title":"再生元制药公司 - 与Catalent Indiana协调解决2025年7月FDA一般现场检查中发现的问题","url":"https://stock-news.laohu8.com/highlight/detail?id=1140117891","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140117891?lang=zh_cn&edition=full","pubTime":"2025-11-20 05:12","pubTimestamp":1763586732,"startTime":"0","endTime":"0","summary":"再生元制药公司 - 与Catalent Indiana协调解决2025年7月FDA一般现场检查中发现的问题","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0823416689.USD","LU0053666078.USD","LU0823434583.USD","LU0889565916.HKD","LU2023250504.SGD","BK4139","LU1974910355.USD","LU0114720955.EUR","LU2362541273.HKD","LU2106854487.HKD","LU0823434740.USD","LU2362541513.USD","LU2089984988.USD","LU1917777945.USD","REGN","LU2468319806.SGD","LU0320765992.SGD","LU0882574055.USD","LU2237438978.USD","BK4588","LU2362540622.SGD","LU0058720904.USD","BK4585","LU0289739699.SGD"],"gpt_icon":0},{"id":"1132722384","title":"Eylea Hd® (Aflibercept) 注射剂 8 毫克通过 FDA 批准用于治疗视网膜静脉阻塞后的黄斑水肿，并可在批准适应症中进行每月给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1132722384","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132722384?lang=zh_cn&edition=full","pubTime":"2025-11-20 05:11","pubTimestamp":1763586676,"startTime":"0","endTime":"0","summary":"Eylea Hd® (Aflibercept) 注射剂 8 毫克已获 FDA 批准，用于治疗视网膜静脉阻塞（Rvo）导致的黄斑水肿，并可在所有批准的适应症中进行每月给药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823434583.USD","BK4588","REGN","LU1917777945.USD","LU2237438978.USD","LU0320765992.SGD","LU2362541273.HKD","LU0053666078.USD","LU2089984988.USD","LU2362540622.SGD","LU0882574055.USD","LU0109394709.USD","LU0114720955.EUR","LU0889565916.HKD","LU2362541513.USD","LU2023250504.SGD","BK4585","LU1974910355.USD","LU2468319806.SGD","LU0823416689.USD","LU0823434740.USD","LU2106854487.HKD","LU0058720904.USD","LU0289739699.SGD","BK4139"],"gpt_icon":0},{"id":"1158394635","title":"再生元制药公司杜比尤单抗关键试验达成所有主要和次要终点，显著减轻过敏性真菌性鼻窦炎症状；sBLA获得FDA优先审查","url":"https://stock-news.laohu8.com/highlight/detail?id=1158394635","media":"投资观察","labels":["policyRegulatory","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158394635?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:08","pubTimestamp":1763572090,"startTime":"0","endTime":"0","summary":"11月7日 - 再生元制药公司宣布：*杜比尤单抗（DUPIXENT®）关键试验达成所有主要和次要终点，显著减轻过敏性真菌性鼻窦炎（AFRS）的体征和症状；sBLA获得FDA优先审查*再生元制药公司：杜比尤单抗的sBLA已被美国FDA接受优先审查，目标行动日期为2026年2月28日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","LU0289739699.SGD","LU2362541513.USD","LU2106854487.HKD","BK4585","BK4588","LU0889565916.HKD","LU0823434740.USD","LU0114720955.EUR","LU2362540622.SGD","LU0823416689.USD","LU0882574055.USD","LU0058720904.USD","BK4139","LU1974910355.USD","LU0053666078.USD","LU1917777945.USD","LU2089984988.USD","LU0320765992.SGD","REGN","LU2468319806.SGD","LU0109394709.USD","LU0823434583.USD","LU2237438978.USD","LU2023250504.SGD"],"gpt_icon":0},{"id":"1196287619","title":"再生元制药公司Libtayo®（Cemiplimab）在欧盟获得批准，成为首个也是唯一用于高复发风险的皮肤鳞状细胞癌术后及放疗辅助治疗的免疫疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1196287619","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196287619?lang=zh_cn&edition=full","pubTime":"2025-11-19 20:10","pubTimestamp":1763554234,"startTime":"0","endTime":"0","summary":"再生元制药公司Libtayo®（Cemiplimab）在欧盟获得批准，成为首个也是唯一用于高复发风险的皮肤鳞状细胞癌（Cscc）术后和放疗的辅助治疗免疫疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250504.SGD","LU2362541513.USD","LU2468319806.SGD","LU0320765992.SGD","LU0823416689.USD","LU0114720955.EUR","BK4139","LU0882574055.USD","LU0889565916.HKD","LU0058720904.USD","LU0109394709.USD","BK4585","BK4588","LU2362540622.SGD","LU1974910355.USD","LU2362541273.HKD","LU0823434583.USD","LU2089984988.USD","LU0053666078.USD","REGN","LU0823434740.USD","LU2106854487.HKD","LU2237438978.USD","LU0289739699.SGD","LU1917777945.USD"],"gpt_icon":0},{"id":"1131407912","title":"赛诺菲与再生元的Dupixent达成关键终点，获FDA优先审查接受","url":"https://stock-news.laohu8.com/highlight/detail?id=1131407912","media":"投资观察","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131407912?lang=zh_cn&edition=full","pubTime":"2025-11-07 21:17","pubTimestamp":1762521460,"startTime":"0","endTime":"0","summary":"11月7日 - 赛诺菲公司：赛诺菲与再生元的Dupixent关键研究满足所有主要和次要终点，减少了过敏性真菌性鼻窦炎的症状和体征；申请已被FDA接受为优先审查。三期研究数据显示，Dupixent减少了鼻部症状和体征。该药物已获得美国FDA的优先审查，目标决定日期为2026年2月28日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN","LU0823416689.USD","LU0823434583.USD","LU0114720955.EUR","LU0889565916.HKD","LU0053666078.USD","LU1974910355.USD","LU1917777945.USD","LU0289739699.SGD","LU2468319806.SGD","LU2023250504.SGD","BK4139","LU0058720904.USD","LU2089984988.USD","LU2237438978.USD","LU0109394709.USD","LU0320765992.SGD","LU0823434740.USD","LU2106854487.HKD","LU2362541513.USD","BK4588","BK4585","LU0882574055.USD","LU2362540622.SGD","LU2362541273.HKD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":0.0261},{"period":"1month","weight":0.0969},{"period":"3month","weight":0.4107},{"period":"6month","weight":0.403},{"period":"1year","weight":0.0858},{"period":"ytd","weight":0.032}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再生元制药公司于1988年在纽约州成立。再生元制药公司是一家完全集成的生物技术公司，它发现、发明、开发、制造和商业化治疗严重疾病的药物。其正在开发的商业化药物和候选产品旨在帮助患有眼疾、过敏性和炎症性疾病、癌症、心血管和代谢性疾病、疼痛、传染病和罕见疾病的患者。它的核心业务战略是在基础科学研究和发现启用技术方面保持坚实的基础，并建立在临床开发、制造和商业能力的基础上。其目标是继续成为一家综合性、多产品的生物技术公司，为患者和医疗专业人员提供预防和治疗人类疾病的重要选择。","yearOnYearQuotes":[{"month":1,"riseRate":0.542857,"avgChangeRate":0.038789},{"month":2,"riseRate":0.411765,"avgChangeRate":0.087815},{"month":3,"riseRate":0.470588,"avgChangeRate":-0.044318},{"month":4,"riseRate":0.470588,"avgChangeRate":0.017191},{"month":5,"riseRate":0.628571,"avgChangeRate":0.057479},{"month":6,"riseRate":0.428571,"avgChangeRate":0.006745},{"month":7,"riseRate":0.657143,"avgChangeRate":0.052646},{"month":8,"riseRate":0.542857,"avgChangeRate":0.022877},{"month":9,"riseRate":0.457143,"avgChangeRate":0.023281},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.485714,"avgChangeRate":0.043803}],"exchange":"NASDAQ","name":"再生元制药公司","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再生元制药公司,REGN,再生元制药公司股票,再生元制药公司股票老虎,再生元制药公司股票老虎国际,再生元制药公司行情,再生元制药公司股票行情,再生元制药公司股价,再生元制药公司股市,再生元制药公司股票价格,再生元制药公司股票交易,再生元制药公司股票购买,再生元制药公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再生元制药公司(REGN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再生元制药公司(REGN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}